SCHEMBL3198772

SCHEMBL3198772

CC(C)c1sc(N)nc1CN1CCCC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 2/20 0.36
RECQL P46063 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.34
TMEM97 Q5BJF2 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
LMNA P02545 4/20 0.32
ALDH1A1 P00352 3/20 0.32
KDM4E B2RXH2 2/20 0.32
HTT P42858 1/20 0.32
ADORA2A P29274 2/20 0.32
ADORA1 P30542 2/20 0.32
HPGD P15428 1/20 0.31
DRD2 P14416 2/20 0.31
MAPT P10636 2/20 0.31
HRH3 Q9Y5N1 2/20 0.31
ADRA2A P08913 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
HTR2A P28223 1/20 0.31
ADRA1A P35348 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL330498 0.73 FBP1 (0.35) RAD52RECQLALDH1A1MAPTHRH1
SCHEMBL3200211 0.73 MEN1 (0.45) ALDH1A1KDM4ECYP2D6
SCHEMBL22276807 0.72 COPS5 (0.39) ALDH1A1KDM4EHPGDFBP1
SCHEMBL3197829 0.66 KMT2A (0.43) LMNAALDH1A1KDM4EADORA2AHPGD
SCHEMBL21607014 0.63 L3MBTL1 (0.39) L3MBTL1LMNAALDH1A1KDM4EADORA2A
SCHEMBL5875623 0.63 NOS1 (0.39) RAD52RECQLALDH1A1MAPTHRH1
SCHEMBL10986635 0.63 FBP1 (0.37) MAPTMAPK1FBP1
SCHEMBL6274521 0.63 NOS1 (0.52) ALDH1A1MAPTHRH1CYP1A2MAPK1
SCHEMBL1107464 0.62 FBP1 (0.36) ALDH1A1CYP1A2FBP1
SCHEMBL22858988 0.61 CYP1A2 (0.46) L3MBTL1LMNAALDH1A1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904494-B1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS LILLY CO ELI (US) 2010-12-01 EP disclosed
US-7666879-B2 Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors ELI LILLY AND COMPANY (US) 2010-02-23 US disclosed
US-20090227622-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS ELI LILLY AND COMPANY 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227622-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS KDR, FLT1, FLT4 RAD52 1123/4885RECQL 2549/4885L3MBTL1 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.